AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00726973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab monotherapy
Description: 3 monthly intravitreal injections of Ranibizumab monotherapy. After month 2 they are eligible for retreatment with Ranibizumab if retreatment criteria are met (same as arm 1) At intervals of no less than 3 months from the previous sham PDT they will receive sham PDT if retreatment criteria are met.
Study NCT03594981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV/AdV /EBV/BKV specific T cells
Description: Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
Study NCT00410332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traumeel S
Description: homeopathic remedy
Study NCT00410332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo drug, identical in size, form and taste as treatment remedy
Study NCT03740087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnivorous diet
Description: Determine if the transfer of bovine miRNAs is carried out after a meal containing beef.
Study NCT03740087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegan diet
Description: Used as a baseline for miRNA levels in blood
Study NCT02921880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Study NCT01859065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified anticipatory guidance
Description: Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
Study NCT01859065 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine
Description: Routine anticipatory guidance (control)
Study NCT05146518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive and Dignified Maternity Care
Description: The core components of intervention would include: capacity-building of a typical maternity team comprising clinical staff (gynaecologists, doctors, nurses) and support staff (ward boys/porters and maids); collaborative care, a team-driven approach, led by gynaecologists (ward in-charge), attempts to integrate care and behaviour practices of staff according to the principles of measurement-guided care-plans, quality improvement and accountability, with a focus on meeting SDMC needs; staff and patient feedback: a complaints register will be maintained by designated staff; and brief exit interviews will elicit, and record, the degree to which care has been supportive and respectful; Accountability and governance (performance review): reports of non-respectful care will be discussed, and remedial actions decided, in periodic meetings.~Note: Since it is a behavioural intervention being administered at health system level so LSHTM has exempted this study to have a sponsor.
Study NCT04212559 — intervention group
Intervention type: OTHER
Intervention: Received negative pressure ventilation
Description: Patients who received a negative pressure during inspiratory phase.
Study NCT04257786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1ry cyto-reductive surgery
Description: 1ry surgery then chemotherapy
Study NCT04257786 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemotherapy followed by surgery
Description: chemotherapy then surgery
Study NCT04132869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sports Readiness Intervention
Description: Sixth graders will participate in a 6 month after-school program in which each daily session will last 90 minutes, 60 minutes of which will be moderate to vigorous physical activity. Two sports tracks will be offered during each 8-week season, and children will choose which they prefer. Coaches will be trained through a one day capacity building session and will receive online training throughout the program. Coaches will integrate sports readiness/physical activity programming, nutrition and healthy eating, and social emotional learning into the program with a focus on habit formation. A text-based platform will be utilized to encourage habits learned in the active portion of the program during June and July as well as on weekends during the intervention. Parents will be sent fliers weekly summarizing concepts addressed, and will be invited to cooking classes to watch students compete.
Study NCT01603849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: Patients allocated to this arm will received treatment with whole brain radiotherapy 25 Gy in 10 fractions.
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 67100 ED 25 mg
Description: 2 capsules of BI 671800 ED 25 mg
Study NCT00326716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir + Ritonavir + Combivir
Description: Capsules, tablets, Oral, initially ATV 300 mg + RTV 100 mg + ZDV/3TC 300/150 mg, dose escalated to ATV 400 mg + RTV 100 mg + ZDV/3TC 300/150 mg, ATV and RTV once daily, lamivudine (ZDV) / zidovudine (3TC) twice daily (BID), up to 36 weeks
Study NCT00723762 — intervention group
Intervention type: PROCEDURE
Intervention: Specimen collection
Description: A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.
Study NCT00502112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lintuzumab
Description: 4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle
Study NCT00502112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
Study NCT04682717 — intervention group
Intervention type: DEVICE
Intervention: perfusion index monitoring for postinduction hypotension
Description: Hemodynamic parameters will be recorded at 1-min intervals till 10 min after intubation. Hypotension will be defined as a drop in SBP to \<30% of baseline or absolute MAP \<60 mmHg. MAP \<55 mmHg (severe hypotension) will be treated immediately by rapid intravenous fluid administration (10 ml/kg) and ephedrine sulphate 6 mg IV boluses. Bradycardia will be defined as HR \<50 bpm or decrease by more than 30% below baseline value, whichever will be lower and will be treated with atropine 0.6 mg IV boluses. The incidence of hypotension will be calculated in 2 sets - 5 min after induction of anesthesia (effect of induction agent) and first 15 min after induction (effect of induction process and endotracheal intubation).
Study NCT02362802 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator
Study NCT05125796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1000 mg intravenous paracetamol in 100 mL normal saline
Study NCT05125796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen Trometamol
Description: 50 mg intravenous dexketoprofen Trometamol in 100 mL normal saline
Study NCT05125796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: Application of 5 gr of 5% topical lidocaine
Study NCT05125796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL intravenous normal saline infusion+ placebo topical pomade application
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 ED placebo
Description: 2 capsules of BI 671800 ED placebo (bid in the morning and evening)
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast placebo tablet
Description: 1 over-encapsulated montelukast placebo tablet (qd in the morning)
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: montelukast placebo tablet
Description: 1 over-encapsulated montelukast placebo tablet (qd in the morning)
Study NCT03181100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03181100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT03181100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study NCT03181100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT03181100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03181100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study NCT01708941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01708941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01708941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV or SC
Study NCT04416269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Anti-diabetes Drugs alone
Description: OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
Study NCT04416269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal bolus insulin
Description: Basal insulin with glargine or detemir will be used as per the hospital formulary.
Study NCT04416269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental insulin
Description: Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG >140 mg/dl.
Study NCT04416269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental insulin
Description: Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG >140 mg/dl.
Study NCT04416269 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring (CGM)
Description: A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes.
Study NCT04416269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Description: A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes.
Study NCT03123445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar,30mg continuous intravenous injection pump, d1-d7,21 days as one cycle, 4 cycles in total
Study NCT03123445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total
Study NCT03123445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total
Study NCT03123445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total
Study NCT03123445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total
Study NCT01965340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic Therapeutic Drug Monitoring for the intervention group
Study NCT05270616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic surgery
Description: minimally invasive surgery using the Davinci robotic system
Study NCT05270616 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uniport surgery
Description: VATS minimally invasive surgery under the uniportal status
Study NCT05270616 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: multiple- port surgery
Description: VATS minimally invasive surgery under the multiple- port status
Study NCT01455597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3011 Estradiol Vaginal Cream
Description: WC3011 estradiol vaginal cream, 3 times a week for 40 weeks.
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate placebo nasal spray
Description: fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
Study NCT02968420 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Papillomavirus 9-valent Vaccine, Recombinant
Description: All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.
Study NCT03119467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP4010
Description: Escalating doses starting at 25 mg
Study NCT02810054 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Minimally Invasive Surgical Techniques (MIST)
Description: Using minimally invasive surgical techniques.
Study NCT02810054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgical Techniques (MIST)
Description: Using minimally invasive surgical techniques.
Study NCT02810054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD)
Description: Use of enamel matrix derivative for the treatment of intrabony periodontal defects.
Study NCT03755830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.
Study NCT03755830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.
Study NCT03074630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 5 weeks 10mg dapagliflozin once daily
Study NCT03074630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 9 weeks 10mg dapagliflozin once daily
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate placebo nasal spray
Description: fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 ED 100 mg
Description: 4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
Study NCT03961568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: active drug
Study NCT04468659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: IV infusion.
Study NCT03780881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation confirmation
Description: Participants receive manipulated feedback indicating that their performance was above average in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
Study NCT03780881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation disconfirmation
Description: Participants receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 671800 ED placebo
Description: 4 capsules of BI 671800 ED placebo (bid in the morning and evening)
Study NCT01681212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT01681212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Study NCT04468659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion.
Study NCT04174391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Description: Dietary advice on how to follow a Mediterranean diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. A total of 0.5l/week of EVOO for free will be received by participants of this group. In addition, advice on physical activity will be provided.
Study NCT04174391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat diet
Description: Dietary advice on how to follow a low-fat diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. Allotments of commercial foods - equivalent to the extra-virgin olive oil allotment - will be received by participants of this group for free. In addition, advice on physical activity will be provided.
Study NCT06458868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: salt water or tap water before UVA
Description: Instead of using standard bath PUVA, this study investigates the efficacy of tap water or salt water with UVA in the treatment of palmoplantar psoriasis.
Study NCT04615104 — intervention group
Intervention type: PROCEDURE
Intervention: Operative
Description: surgical treatment
Study NCT01480466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obesity tools in the electronic health record
Description: The intervention is a set of new tools within the Partners electronic health record that are designed to assist primary care clinicians with the assessment and management of overweight and obesity in their patients.
Study NCT04615104 — intervention group
Intervention type: PROCEDURE
Intervention: Nonoperative
Description: nonsurgical treatment
Study NCT02085408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Given IV
Study NCT02085408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV
Study NCT02085408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV
Study NCT02085408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT02085408 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Undergo clinical observation
Study NCT02085408 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
Study NCT02085408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
Study NCT03387553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine (DC1)
Description: Study Vaccine:~Lead In Phase - Weekly as outlined in each treatment Arm.~Expansion Phase - At the optimal schedule determined at the end of the Lead In Phase.~Pre-surgery - Booster Vaccine at week 25 prior to receiving surgery.~Post-surgery - Participants will receive a series of 3 booster intranodal study vaccines given once every 6 months.
Study NCT03387553 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic Cell Vaccine (DC1)
Description: Study Vaccine:~Lead In Phase - Weekly as outlined in each treatment Arm.~Expansion Phase - At the optimal schedule determined at the end of the Lead In Phase.~Pre-surgery - Booster Vaccine at week 25 prior to receiving surgery.~Post-surgery - Participants will receive a series of 3 booster intranodal study vaccines given once every 6 months.
Study NCT03387553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: Upon completion of the 3 week series of vaccinations participants will then undergo neoadjuvant chemotherapy treatment with the TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen given intravenously once every 3 weeks for up to 6 cycles. The treating physician will have the discretion to delay, modify, or shorten the neoadjuvant chemotherapy as per routine practice guidelines and physician discretion.